Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.1 (1y: +73%)
Market Cap 173.63 M P/E(ttm)
Enterprise Value 149.32 M P/B 4.11
NSPH- NAS (USA)
Nanosphere, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.10
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt No Debt
NSPH's Cash to Debt is ranked higher than
87% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.43 vs. NSPH: No Debt )
NSPH' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: No Debt
Equity to Asset 0.832
NSPH's Equity to Asset is ranked higher than
90% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.47 vs. NSPH: 0.832 )
NSPH' s 10-Year Equity to Asset Range
Min: -5.5   Max: 0.87
Current: 0.83
-5.5
0.87
Interest Coverage No Debt
NSPH's Interest Coverage is ranked higher than
85% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 46.10 vs. NSPH: No Debt )
NSPH' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 4.24
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -648.00
NSPH's Operating margin (%) is ranked lower than
94% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NSPH: -648.00 )
NSPH' s 10-Year Operating margin (%) Range
Min: -2890.1   Max: -648
Current: -648
-2890.1
-648
Net-margin (%) -647.3
NSPH's Net-margin (%) is ranked lower than
94% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.30 vs. NSPH: -647.3 )
NSPH' s 10-Year Net-margin (%) Range
Min: -4551.7   Max: -393.9
Current: -647.3
-4551.7
-393.9
ROE (%) -77.8
NSPH's ROE (%) is ranked lower than
85% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NSPH: -77.8 )
NSPH' s 10-Year ROE (%) Range
Min: -91.2   Max: -42.9
Current: -77.8
-91.2
-42.9
ROA (%) -69.3
NSPH's ROA (%) is ranked lower than
92% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. NSPH: -69.3 )
NSPH' s 10-Year ROA (%) Range
Min: -212.2   Max: -38.3
Current: -69.3
-212.2
-38.3
ROC (Joel Greenblatt) (%) -523.60
NSPH's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.00 vs. NSPH: -523.60 )
NSPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1408.1   Max: -511
Current: -523.6
-1408.1
-511
EBITDA Growth (%) -16.7
NSPH's EBITDA Growth (%) is ranked higher than
60% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. NSPH: -16.7 )
NSPH' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 25.1
Current: -16.7
0
25.1
EPS Growth (%) -17.7
NSPH's EPS Growth (%) is ranked higher than
60% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.15 vs. NSPH: -17.7 )
NSPH' s 10-Year EPS Growth (%) Range
Min: -59.2   Max: 34.3
Current: -17.7
-59.2
34.3
ยป NSPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q4 2011

NSPH Guru Trades in Q4 2011

Jim Simons 238,363 sh (+77.47%)
» More
Q1 2012

NSPH Guru Trades in Q1 2012

Jim Simons 150,899 sh (-36.69%)
» More
Q2 2012

NSPH Guru Trades in Q2 2012

Jim Simons 37,400 sh (-75.22%)
» More
Q3 2012

NSPH Guru Trades in Q3 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NSPH



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 4.11
NSPH's P/B is ranked lower than
65% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. NSPH: 4.11 )
NSPH' s 10-Year P/B Range
Min: 0.81   Max: 5.08
Current: 4.11
0.81
5.08
P/S 25.83
NSPH's P/S is ranked lower than
97% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. NSPH: 25.83 )
NSPH' s 10-Year P/S Range
Min: 8.41   Max: 188.83
Current: 25.83
8.41
188.83
EV-to-EBIT -4.47
NSPH's EV-to-EBIT is ranked higher than
94% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.12 vs. NSPH: -4.47 )
NSPH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.47

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 6.3
NSPH's Price/Net Cash is ranked higher than
77% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.40 vs. NSPH: 6.3 )
NSPH' s 10-Year Price/Net Cash Range
Min: 0.6   Max: 5.1
Current: 6.3
0.6
5.1
Price/Net Current Asset Value 35.3
NSPH's Price/Net Current Asset Value is ranked higher than
91% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.40 vs. NSPH: 35.3 )
NSPH' s 10-Year Price/Net Current Asset Value Range
Min: 2.4   Max: 48.4
Current: 35.3
2.4
48.4
Price/Tangible Book 4.4
NSPH's Price/Tangible Book is ranked higher than
65% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NSPH: 4.4 )
NSPH' s 10-Year Price/Tangible Book Range
Min: 0.5   Max: 3.6
Current: 4.4
0.5
3.6
Price/Median PS Value 0.9
NSPH's Price/Median PS Value is ranked higher than
54% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.90 vs. NSPH: 0.9 )
NSPH' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 2.1
Current: 0.9
0.5
2.1
Forward Rate of Return (Yacktman) -118.27
NSPH's Forward Rate of Return (Yacktman) is ranked lower than
60% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.11 vs. NSPH: -118.27 )
NSPH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 22.3   Max: 55.8
Current: -118.27
22.3
55.8

Business Description

Nanosphere, Inc. is a Delaware Corporation. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Its proprietary nanoparticle technology provides the ability to run multiple tests simultaneously on the same sample. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. While many systems currently available on the market provide a diagnostic result for one test or a few tests within a specific market niche, the Verigene System provides for multiple tests to be performed on a single platform, including both genomic and protein assays, from a single sample. The Verigene System is differentiated by its ease of use, rapid turnaround times and ability to detect many targets on a single test, referred to as 'multiplexing.' It provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO
Traded in other countries:3NS.Germany
ยป More Articles for NSPH

Headlines

Articles On GuruFocus.com
NANOSPHERE, INC. Reports Operating Results (10-Q) Aug 05 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 06 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) Nov 05 2009 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 08 2009 

More From Our Partners
Morning Market Movers May 14 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial